Cargando…

Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer

Several preclinical studies suggested a potential benefit from combined treatment with inhibitors of epidermal growth factor receptor (EGFR) and angiogenesis, both effective in patients with advanced non-small-cell lung cancer (NSCLC). In pretreated patients with advanced EGFR wild type NSCLC, bevac...

Descripción completa

Detalles Bibliográficos
Autores principales: Palumbo, Giuliano, Esposito, Giovanna, Carillio, Guido, Manzo, Anna, Montanino, Agnese, Sforza, Vincenzo, Costanzo, Raffaele, Sandomenico, Claudia, La Manna, Carmine, Martucci, Nicola, La Rocca, Antonello, De Luca, Giuseppe, Piccirillo, Maria Carmela, De Cecio, Rossella, Perrone, Francesco, Totaro, Giuseppe, Muto, Paolo, Picone, Carmine, Normanno, Nicola, Morabito, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Open Exploration 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400697/
https://www.ncbi.nlm.nih.gov/pubmed/36046069
http://dx.doi.org/10.37349/etat.2020.00008
_version_ 1784772798586028032
author Palumbo, Giuliano
Esposito, Giovanna
Carillio, Guido
Manzo, Anna
Montanino, Agnese
Sforza, Vincenzo
Costanzo, Raffaele
Sandomenico, Claudia
La Manna, Carmine
Martucci, Nicola
La Rocca, Antonello
De Luca, Giuseppe
Piccirillo, Maria Carmela
De Cecio, Rossella
Perrone, Francesco
Totaro, Giuseppe
Muto, Paolo
Picone, Carmine
Normanno, Nicola
Morabito, Alessandro
author_facet Palumbo, Giuliano
Esposito, Giovanna
Carillio, Guido
Manzo, Anna
Montanino, Agnese
Sforza, Vincenzo
Costanzo, Raffaele
Sandomenico, Claudia
La Manna, Carmine
Martucci, Nicola
La Rocca, Antonello
De Luca, Giuseppe
Piccirillo, Maria Carmela
De Cecio, Rossella
Perrone, Francesco
Totaro, Giuseppe
Muto, Paolo
Picone, Carmine
Normanno, Nicola
Morabito, Alessandro
author_sort Palumbo, Giuliano
collection PubMed
description Several preclinical studies suggested a potential benefit from combined treatment with inhibitors of epidermal growth factor receptor (EGFR) and angiogenesis, both effective in patients with advanced non-small-cell lung cancer (NSCLC). In pretreated patients with advanced EGFR wild type NSCLC, bevacizumab plus erlotinib improved progression-free survival as second-line therapy in the BeTa study and as maintenance therapy in the ATLAS trial, although the benefit was modest and did not translate into an advantage in overall survival. Disappointing results were reported with oral VEGF inhibitors plus erlotinib in pretreated patients with EGFR wild type NSCLC. On the contrary, erlotinib plus bevacizumab or ramucirumab showed a clinically relevant improvement of progression-free survival in naïve patients with EGFR mutations, leading to the approval of these two regimens as first-line treatment of NSCLC patients with EGFR mutant tumors. Several clinical studies are evaluating the feasibility and activity of osimertinib plus bevacizumab or ramucirumab. However, limits that could affect its use in clinical practice are the need of an intravenous infusion for angiogenesis inhibitors, the increased incidence of treatment associated adverse events, the exclusion of patients with tumors located in central position or at risk of hemorrhage. The identification of predictive biomarkers is an important goal of research to optimize the combined use of these agents.
format Online
Article
Text
id pubmed-9400697
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Open Exploration
record_format MEDLINE/PubMed
spelling pubmed-94006972022-08-30 Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer Palumbo, Giuliano Esposito, Giovanna Carillio, Guido Manzo, Anna Montanino, Agnese Sforza, Vincenzo Costanzo, Raffaele Sandomenico, Claudia La Manna, Carmine Martucci, Nicola La Rocca, Antonello De Luca, Giuseppe Piccirillo, Maria Carmela De Cecio, Rossella Perrone, Francesco Totaro, Giuseppe Muto, Paolo Picone, Carmine Normanno, Nicola Morabito, Alessandro Explor Target Antitumor Ther Review Several preclinical studies suggested a potential benefit from combined treatment with inhibitors of epidermal growth factor receptor (EGFR) and angiogenesis, both effective in patients with advanced non-small-cell lung cancer (NSCLC). In pretreated patients with advanced EGFR wild type NSCLC, bevacizumab plus erlotinib improved progression-free survival as second-line therapy in the BeTa study and as maintenance therapy in the ATLAS trial, although the benefit was modest and did not translate into an advantage in overall survival. Disappointing results were reported with oral VEGF inhibitors plus erlotinib in pretreated patients with EGFR wild type NSCLC. On the contrary, erlotinib plus bevacizumab or ramucirumab showed a clinically relevant improvement of progression-free survival in naïve patients with EGFR mutations, leading to the approval of these two regimens as first-line treatment of NSCLC patients with EGFR mutant tumors. Several clinical studies are evaluating the feasibility and activity of osimertinib plus bevacizumab or ramucirumab. However, limits that could affect its use in clinical practice are the need of an intravenous infusion for angiogenesis inhibitors, the increased incidence of treatment associated adverse events, the exclusion of patients with tumors located in central position or at risk of hemorrhage. The identification of predictive biomarkers is an important goal of research to optimize the combined use of these agents. Open Exploration 2020 2020-04-28 /pmc/articles/PMC9400697/ /pubmed/36046069 http://dx.doi.org/10.37349/etat.2020.00008 Text en © The Author(s) 2020. https://creativecommons.org/licenses/by/4.0/This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Palumbo, Giuliano
Esposito, Giovanna
Carillio, Guido
Manzo, Anna
Montanino, Agnese
Sforza, Vincenzo
Costanzo, Raffaele
Sandomenico, Claudia
La Manna, Carmine
Martucci, Nicola
La Rocca, Antonello
De Luca, Giuseppe
Piccirillo, Maria Carmela
De Cecio, Rossella
Perrone, Francesco
Totaro, Giuseppe
Muto, Paolo
Picone, Carmine
Normanno, Nicola
Morabito, Alessandro
Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer
title Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer
title_full Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer
title_fullStr Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer
title_full_unstemmed Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer
title_short Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer
title_sort angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400697/
https://www.ncbi.nlm.nih.gov/pubmed/36046069
http://dx.doi.org/10.37349/etat.2020.00008
work_keys_str_mv AT palumbogiuliano angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer
AT espositogiovanna angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer
AT carillioguido angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer
AT manzoanna angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer
AT montaninoagnese angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer
AT sforzavincenzo angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer
AT costanzoraffaele angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer
AT sandomenicoclaudia angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer
AT lamannacarmine angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer
AT martuccinicola angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer
AT laroccaantonello angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer
AT delucagiuseppe angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer
AT piccirillomariacarmela angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer
AT dececiorossella angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer
AT perronefrancesco angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer
AT totarogiuseppe angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer
AT mutopaolo angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer
AT piconecarmine angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer
AT normannonicola angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer
AT morabitoalessandro angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer